AstraZeneca delivers 68 million COVID shots in 1st quarter
AstraZeneca says it delivered about 68 million doses of its COVID-19 vaccine during the first three months of 2021 after the shot became one of the first approved for widespread use
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AstraZeneca says it delivered about 68 million doses of its COVID-19 vaccine during the first three months of 2021 after the shot became one of the first approved for widespread use.
The Anglo-Swedish drugmaker on Friday reported $275 million in revenue from sales of the vaccine, or the equivalent of $4.04 per dose. AstraZeneca has pledged that it will deliver the vaccine on a non-profit basis as long as the pandemic lasts.
The company said 30 million doses of the vaccine went to the European Union 26 million to the U.K., 7 million to Gavi, an alliance that secures vaccines for low-income countries, and 5 million to other nations.
The vaccine was developed by researchers at Oxford University, who licensed the technology to AstraZeneca in an effort to tap into the company’s global manufacturing and distribution capacity.
Regulators in several jurisdictions, including the U.K., European Union and India have authorized widespread use of the AstraZeneca vaccine, though the U.S. Food and Drug Administration has not.
Concern that the AstraZeneca vaccine may be linked to rare blood clots has led some countries to recommend that it not be used in younger people.